In The News

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Myeloma UK Launches Research Program Focused on Trial Design
    by Mary Chapman on July 19, 2019 at 1:54 pm

    In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research program. Called the UK Myeloma Research Alliance-Myeloma UK-Concept and Access Research Program (UKMRA-Myeloma UK-CARP), the grant initiative seeks to build upon the success of the 10-year-old Myeloma UK Clinical Trials Network (CTN). […] The post Myeloma UK Launches Research Program Focused on Trial Design appeared first on Myeloma Research News. […]

  • Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA
    by Joana Carvalho on July 17, 2019 at 1:47 pm

    Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a faster and easier treatment for people with multiple myeloma. Currently, Darzalex is approved as an intravenous infusion into a vein that takes several hours. The biologics license application (BLA) request, if approved, offers the option […] The post Request for Darzalex as Faster and Easier Under-the-skin Infusion for Multiple Myeloma Before FDA appeared first on Myeloma Research News. […]

  • Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests
    by Patricia Inacio, PhD on July 15, 2019 at 4:08 pm

    A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new study suggests. Testing for this rearrangement of chromosomes may help better stratify patients according to their risk of disease progression and tailor their treatment regimens. “This could be different than […] The post Specific DNA Rearrangement Predicts Treatment Resistance, Poor Outcomes in Multiple Myeloma, Study Suggests appeared first on Myeloma Research News. […]

  • FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma
    by Patricia Inacio, PhD on July 12, 2019 at 12:00 pm

    The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential therapy for patients with hard-to-treat multiple myeloma, the company announced. FDA’s final decision about whether to approve isatuximab is expected by April 30, 2020, according to a press release. Isatuximab is a monoclonal antibody […] The post FDA Will Review Isatuximab as Potential Therapy for Hard-to-treat Multiple Myeloma appeared first on Myeloma Research News. […]

  • FDA Lifts Hold on Phase 3 Trial Testing Venclexta in Myeloma Patients with Common Genetic Abnormality
    by Marisa Wexler on July 10, 2019 at 11:53 am

    The U.S. Food and Drug Administration (FDA) has lifted its hold on the CANOVA Phase 3 clinical trial, which is evaluating the experimental therapeutic Vencexta (venetoclax) plus dexamethasone in people with relapsed or refractory multiple myeloma who test positive for a common genetic abnormality. Venclexta (sold as Venclyxto in Europe), developed jointly by AbbVie and Roche, […] The post FDA Lifts Hold on Phase 3 Trial Testing Venclexta in Myeloma Patients with Common Genetic Abnormality appeared first on Myeloma Research News. […]